SBI Securities’s Apellis Pharmaceuticals APLS Stock Holding History

SBI Securities’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-257	Closed	-$10.3K	–	4073
2026 Q1	$10.3K	Buy	257 +120	+88%	+$2.59K	﹤0.01%	1704
2025 Q4	$3.44K	Buy	137 +44	+47%	+$1.03K	﹤0.01%	2182
2025 Q3	$2.1K	Buy	93 +2	+2%	+$47	﹤0.01%	2399
2025 Q2	$1.57K	Buy	91 +2	+2%	+$37	﹤0.01%	2494
2025 Q1	$1.95K	Buy	89 +4	+5%	+$111	﹤0.01%	2303
2024 Q4	$2.71K	Buy	+85	New	+$2.56K	﹤0.01%	2179

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities's APLS Position: Q2 2026 in Review

SBI Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 257 shares — an estimated $10.3K sold.

SBI Securities first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $10.3K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

SBI Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SBI Securities sold 257 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.3K.
SBI Securities first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
SBI Securities's Apellis Pharmaceuticals position peaked at $10.3K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.